Additionally, TAB2 has been reported to serve as a new target for tamoxifen resistance in breast cancer 40, and down-regulation of TAB2 may sensitize NSCLC cells to BMS-690514, a new pan-HER/VEGFR inhibitor 41. Here, KDR is linked to non-small cell lung carcinoma.